Literature DB >> 34414554

Prognostic value of myocardial flow reserve obtained by 82-rubidium positron emission tomography in long-term follow-up after heart transplantation.

Lærke Marie Nelson1, Thomas Emil Christensen2,3, Kasper Rossing4, Philip Hasbak2, Finn Gustafsson4,5.   

Abstract

BACKGROUND: Cardiac allograft vasculopathy (CAV) is a leading cause of death following heart transplantation (HTx) and non-invasive prognostic methods in long-term CAV surveillance are needed. We evaluated the prognostic value of myocardial flow reserve (MFR) obtained by 82-rubidium (82Rb) positron emission tomography (PET).
METHODS: Recipients undergoing dynamic rest-stress 82Rb PET between April 2013 and June 2017 were retrospectively evaluated in a single-center study. Evaluation by PET included quantitative myocardial blood flow and semiquantitative myocardial perfusion imaging. Patients were grouped by MFR (MFR ≤ 2.0 vs MFR > 2.0) and the primary outcome was all-cause mortality.
RESULTS: A total of 50 patients (68% men, median age 57 [IQR: 43 to 68]) were included. Median time from HTx to PET was 10.0 (6.7 to 16.0) years. In 58% of patients CAV was documented prior to PET. During a median follow-up of 3.6 (2.3 to 4.3) years 12 events occurred. Survival probability by Kaplan-Meier method was significantly higher in the high-MFR group (log-rank P = .02). Revascularization (n = 1), new CAV diagnosis (n = 1), and graft failure (n = 4) were more frequent in low-MFR patients. No retransplantation occurred.
CONCLUSIONS: Myocardial flow reserve appears to offer prognostic value in selected long-term HTx recipients and holds promise as a non-invasive method for CAV surveillance possibly guiding management strategy.
© 2021. American Society of Nuclear Cardiology.

Entities:  

Keywords:  Cardiac allograft vasculopathy; Heart transplantation; Myocardial blood flow; Myocardial flow reserve; Positron emission tomography; Prognosis; Surveillance

Mesh:

Substances:

Year:  2021        PMID: 34414554     DOI: 10.1007/s12350-021-02742-3

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   3.872


  5 in total

1.  Prognostic value of rubidium-82 positron emission tomography in patients after heart transplant.

Authors:  Brian A Mc Ardle; Ross A Davies; Li Chen; Gary R Small; Terrence D Ruddy; Girish Dwivedi; Yeung Yam; Haissam Haddad; Lisa M Mielniczuk; Ellamae Stadnick; Renee Hessian; Ann Guo; Rob S Beanlands; Robert A deKemp; Benjamin J W Chow
Journal:  Circ Cardiovasc Imaging       Date:  2014-09-02       Impact factor: 7.792

2.  Diagnostic and prognostic value of myocardial blood flow quantification as non-invasive indicator of cardiac allograft vasculopathy.

Authors:  Paco E Bravo; Brian A Bergmark; Tomas Vita; Viviany R Taqueti; Ankur Gupta; Sara Seidelmann; Thomas E Christensen; Michael T Osborne; Nishant R Shah; Nina Ghosh; Jon Hainer; Courtney F Bibbo; Meagan Harrington; Fred Costantino; Mandeep R Mehra; Sharmila Dorbala; Ron Blankstein; Akshay Desai; Lynne Stevenson; Michael M Givertz; Marcelo F Di Carli
Journal:  Eur Heart J       Date:  2018-01-21       Impact factor: 29.983

Review 3.  Imaging in Heart Transplant Patients.

Authors:  Michael Olymbios; Jacek Kwiecinski; Daniel S Berman; Jon A Kobashigawa
Journal:  JACC Cardiovasc Imaging       Date:  2018-10

4.  Serial Assessment of Coronary Flow Reserve by Rubidium-82 Positron Emission Tomography Predicts Mortality in Heart Transplant Recipients.

Authors:  Attila Feher; Ajay Srivastava; Michael A Quail; Nabil E Boutagy; Pravien Khanna; Lynn Wilson; Edward J Miller; Yi-Hwa Liu; Forrester Lee; Albert J Sinusas
Journal:  JACC Cardiovasc Imaging       Date:  2018-10-17

Review 5.  Myocardial blood flow measurement by PET: technical aspects and clinical applications.

Authors:  Philipp A Kaufmann; Paolo G Camici
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.